



MICHELLE BAASS
DIRECTOR

State of California—Health and Human Services Agency
Department of Health Care Services



GAVIN NEWSOM
GOVERNOR

September 9, 2022

Mr. James G. Scott, Director
Division of Program Operations
Medicaid and CHIP Operations Group
Centers for Medicare & Medicaid Services
601 East 12th Street, Suite 0300
Kansas City, MO 64106-2898

**STATE PLAN AMENDMENT 22-0062: REIMBURSEMENT FOR MONKEYPOX
(MPOX) VACCINE ADMINISTRATION**

Dear Mr. Scott:

The Department of Health Care Services (DHCS) is submitting State Plan Amendment (SPA) 22-0062 for your review and approval. This SPA proposes to establish a reimbursement methodology for monkeypox (Mpox) vaccine administration, effective August 17, 2022.

DHCS is proposing to establish the Medi-Cal FFS reimbursement rates for Mpox vaccine administration at 100 percent of the corresponding Medicare rate for the same or similar service, effective August 17, 2022 through the end of the declared State public health emergency for Mpox. At the conclusion of the declared State public health emergency, the reimbursement methodology is expected to return to the methodology as described in State Plan Attachment 4.19-B. Additionally, DHCS proposes to reimburse Federally Qualified Health Centers, Rural Health Clinics, and Tribal Health Programs providers a supplemental amount for Mpox vaccine only visits. This alternative payment methodology will be additional reimbursement above the applicable Prospective Payment Systems (PPS)/alternative payment methodology (APM) approved in State Plan Attachment 4.19-B. This APM will reimburse clinics an additional payment equal to the established FFS rate when an Mpox vaccine is administered on its own. DHCS met with the Centers for Medicare and Medicaid Services (CMS) on August 22, 2022, and this SPA reflects the technical advice that CMS provided.

DHCS published the public notice for SPA 22-0062 on August 16, 2022. In addition, CMS approved our request on August 18, 2022, for an expedited tribal notice, which we published on August 23, 2022. DHCS held the tribal webinar on August 26, 2022.

Mr. James G. Scott
Page 2
September 9, 2022

If you have any questions or need additional information, please contact Lisa Murawski, Chief, Benefits Division, by telephone at (916) 345-8240, or by email at Lisa.Murawski@dhcs.ca.gov.

Sincerely,



Jacey Cooper
State Medicaid Director
Chief Deputy Director
Health Care Programs

Enclosures

cc: Ms. René Mollow, MSN, RN
Deputy Director
Health Care Benefits & Eligibility
Department of Health Care Services
Rene.Mollow@dhcs.ca.gov

Ms. Lindy Harrington
Deputy Director
Health Care Financing
Department of Health Care Services
Lindy.Harrington@dhcs.ca.gov

Ms. Lisa Murawski, Chief
Benefits Division
Department of Health Care Services
Lisa.Murawski@dhcs.ca.gov

Ms. Saralyn M. Ang-Olson, JD, MPP
Chief Compliance Officer
Office of Compliance
Department of Health Care Services
Saralyn.Ang-Olson@dhcs.ca.gov

Mr. Aaron Toyama
Senior Advisor
Health Care Programs
Department of Health Care Services
Aaron.Toyama@dhcs.ca.gov

**TRANSMITTAL AND NOTICE OF APPROVAL OF
STATE PLAN MATERIAL
FOR: CENTERS FOR MEDICARE & MEDICAID SERVICES**

1. TRANSMITTAL NUMBER

2 2 — 0 0 6 2

2. STATE

CA

3. PROGRAM IDENTIFICATION: TITLE OF THE SOCIAL
SECURITY ACT



XIX



XXI

4. PROPOSED EFFECTIVE DATE

August 17, 2022

TO: CENTER DIRECTOR

CENTERS FOR MEDICAID & CHIP SERVICES

DEPARTMENT OF HEALTH AND HUMAN SERVICES

5. FEDERAL STATUTE/REGULATION CITATION

SSA 1905(a)(2), (5), (6), (9), (13), (21); 42 CFR 440.20, 440.50, 440.60, 40.90,
440.130(c), 440.166; 42 CFR 447, Subpart F

6. FEDERAL BUDGET IMPACT (Amounts in WHOLE dollars)

a. FFY 2022 \$ 75,000

b. FFY 2023 \$ 111,000

7. PAGE NUMBER OF THE PLAN SECTION OR ATTACHMENT

Attachment 4.19-B, pages 3S, 6AA4, and 6AA5

8. PAGE NUMBER OF THE SUPERSEDED PLAN SECTION
OR ATTACHMENT (If Applicable)

None

9. SUBJECT OF AMENDMENT

Reimbursement methodology for vaccine administration for monkeypox (Mpox)

10. GOVERNOR'S REVIEW (Check One)



GOVERNOR'S OFFICE REPORTED NO COMMENT



COMMENTS OF GOVERNOR'S OFFICE ENCLOSED



NO REPLY RECEIVED WITHIN 45 DAYS OF SUBMITTAL



OTHER, AS SPECIFIED:

Please note: The Governor's Office does not wish to review
the State Plan Amendment.

11. SIGNATURE OF STATE AGENCY OFFICIAL

[Redacted Signature]

12. TYPED NAME

Jacey Cooper

13. TITLE

State Medicaid Director

14. DATE SUBMITTED

September 9, 2022

15. RETURN TO

Department of Health Care Services

Attn: Director's Office

P.O. Box 997413, MS 0000

Sacramento, CA 95899-7413

FOR CMS USE ONLY

16. DATE RECEIVED

17. DATE APPROVED

PLAN APPROVED - ONE COPY ATTACHED

18. EFFECTIVE DATE OF APPROVED MATERIAL

19. SIGNATURE OF APPROVING OFFICIAL

20. TYPED NAME OF APPROVING OFFICIAL

21. TITLE OF APPROVING OFFICIAL

22. REMARKS

STATE PLAN UNDER TITLE XIX OF THE SOCIAL SECURITY ACT
STATE: California

REIMBURSEMENT METHODOLOGY FOR VACCINE ADMINISTRATION TO
RESPOND TO THE MONKEYPOX PUBLIC HEALTH EMERGENCY

1. Notwithstanding any other provision in this Attachment, the reimbursement rates for administration of the Monkeypox (Mpox) vaccine will be established at 100 percent of the corresponding Medicare rate for the same or similar service, effective August 17, 2022, through the end of the State public health emergency that was declared on August 1, 2022, as a result of the Mpox outbreak.
 - a. The services described in this section are exempt from the ten percent payment reduction described in paragraph (13) on page 3.3 of this Attachment.
 - b. All Medi-Cal Fee-For-Service rates for Mpox vaccine services are published at: <https://files.medi-cal.ca.gov/rates/rateshome.aspx>.
 - c. At the conclusion of the State public health emergency, the reimbursement rates for Mpox vaccine administration will return to the Medi-Cal Fee-For-Service rates in effect as of July 31, 2022.

STATE PLAN UNDER TITLE XIX OF THE SOCIAL SECURITY ACT
STATE: California

A1. ALTERNATIVE PAYMENT METHODOLOGY (APM) for payments to Federally Qualified Health Centers (FQHC), Rural Health Clinics (RHC) and Tribal Federally Qualified Health Center (Tribal FQHCs) for Monkeypox (Mpox) vaccine administration.

a. APM Reimbursement:

- i. The APM for the Mpox vaccine administration when administered during a Mpox vaccine-only visit will be a separate supplemental payment in lieu of the applicable Prospective Payment Systems (PPS) rate or applicable alternative payment methodology (APM) for a medical visit as described in this Attachment beginning at page 6.
- ii. The supplemental payment will be available at the applicable fee-for-service rate for Mpox vaccine administration when the Mpox vaccine is administered during a Mpox vaccine-only visit.
- iii. The Mpox APM supplemental payment will be separate from PPS reimbursement is excluded from the reconciliation of the clinics' reimbursement to the PPS rate.

b. APM Pilot Term:

- i. Dates of service from August 17, 2022, through the end of the State public health emergency that was declared on August 1, 2022, as a result of the Mpox outbreak.

c. Eligible Services:

- i. Mpox vaccine administration pursuant to section 319 of the Public Health Service (PHS) Act, Public Health Emergency (PHE) Determination as the Result of the Consequences of Monkeypox, and as described further below, when administered during a Mpox vaccine-only visit.

d. Excluded Services:

- i. Visits that include Mpox vaccine administration in addition to other medical services eligible for PPS reimbursement are not eligible for this APM.
- ii. Mpox vaccine-only visits that are reimbursable by a Medi-Cal managed care plan are not eligible for this APM. Medi-Cal managed care plan reimbursement for Mpox vaccine-only visits will be excluded from the reconciliation of clinics' reimbursement to the PPS rate.

STATE PLAN UNDER TITLE XIX OF THE SOCIAL SECURITY ACT
STATE: California

- e. Billing Requirements: In order to bill the supplemental payment portion of the APM for Mpox vaccine administration, the code(s) for Monkeypox vaccine must be used, and the provider will be reimbursed the corresponding supplemental payment amount for that code based on the reimbursement methodology described on Attachment 4.19-B, Page 3S.